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 II. Summary 
 
Deciphering molecular pathways, which are involved in cancer development is a key step to 
optimize and individualize treatment against tumor cells while, reducing toxicity to normal 
tissue. Since the tumor suppressor p53 is the most commonly mutated or depleted gene in 
human cancer (Lowe et al, 2004; Vousdan et al, 2009; Chipuk and Green, 2006) my research is 
focussing on elucidating the signaling cascades either initiated by or upstream of p53 with the 
goal to identify novel molecular targets to decrease the threshold in treatment-resistant cancer 
cells. The tumor suppressor p53 is a transcriptional regulator with a sequence-specific DNA-
binding site, thus can also be functional in a transcription-independent manner directly at the 
mitochondrial membrane (Moll et al., 2005). Mechanistically, p53 acts as a sensor of cellular 
stress (Giaccia and Kastan, 1998). Triggered by a variety of stimuli such as DNA damage and 
metabolic stress, the amount of p53 protein rises and the p53-dependent cascade is induced, 
including cell cycle arrest, DNA damage repair or cell death which determines cell fate (Lowe 
et al., 2004). However, how the key decision between life and death is made is not fully 
understood. Further elucidating these p53-induced signalling cascades will give us a novel 
approach to specific and successful targeting strategies against cancer. 
 
III. Crosstalk between Chk1 and Chk2 in double mutant thymocytes (Zaugg et al, 2007,  
Proc Natl Acad Sci U S A) 
 
III.1. Summary 
To further elucidate the signal transduction pathway triggered by DNA damage, we focussed 
on Chk1, a key player in the DNA damage pathway and a kinase that activates p53 (Harris et 
al, 2005; Nevanlinna et al, 2006; Zhou and Elledge, 2000; Vousden et al, 2002). Since 
radiotherapy and many anticancer drugs are strong inducers of the DNA damage pathway, 
Chk1 is considered a good molecular target to increase sensitivity to cancer treatment, 
especially in tumour cells deficient in G1 checkpoint. But in vitro data show that Chk1 plays 
an essential role in normal tissue, especially by contributing to the maintenance of genomic 
stability by controlling cell division and DNA replication, which might be counteracting its 
function as a promising molecular target for cancer treatment (Bartek et al, 2003). Since Chk1-
knockout mice are embryonic lethal, relatively little is known about its true cellular function 
(Liu et al, 2000; Takai et al, 2000; Lam et al, 2004). Therefore, we generated mice with a 
conditional deletion of Chk1 exclusively in the T-cell lineage to better understand the 
physiological function of Chk1 and its role in carcinogenesis. Despite the fact that Chk1 
deletion is highly lethal in proliferating tissues, we succeeded by using a novel in vivo 
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 phospho-flow cytometric technique to generate the first reported Chk1/Chk2 double knockout 
T cells. We provide evidence that the absence of Chk1 leads to cell death in early thymic 
development, due to an increase in apoptosis at the DN2 and DN3 stages. T-cells depleted of 
Chk1 showed activation of checkpoint kinase Chk2 and the tumour suppressor p53. 
Surprisingly, cell death in early T-cell development caused by Chk1 deletion was not rescued 
by p53, p21 or Brca1 inactivation.  
 
III.2. Significance 
Survival of an organism depends on the faithful transmission of genetic information from one 
cell to its daughter cell, which is tightly regulated by the checkpoint kinases. Therefore within 
recent years a lot of research has been performed to better understand the regulation and 
interaction of this signal transduction cascade (Carrassa, 2011). Since dysfunction or mutations 
of the checkpoint kinase pathways plays a crucial role in the pathogenesis of human cancers, 
checkpoint inhibitors seem promising anticancer agents to increase sensitivity to cancer 
treatment.  
For the first time, we report data investigating Chk1-depleted T-cells and their genetic 
interaction with other genes of the checkpoint network. We and others provide strong evidence 
that Chk1 is critical for survival of normal proliferating tissue. These data advise caution to use 
Chk1 as a anticancer agent, since it would crucially influence both normal as well as tumor 
tissue. In fact, the Chk1 inhibitors have failed to show high level of clinical activity, most 
likely due to compensatory activation of other pathways like ATM/Chk2, as provided by us 
and other research groups (Dent et al, 2011).   
 
IV. Carnitine Palmitoyltransferase 1C Promotes Cell Survival and Tumor Growth under 
Conditions of Metabolic Stress (Zaugg et al, Genes and Development, 2011) 
 
IV.1. Summary 
Tumor cells undergo metabolic adaptation in response to metabolic stress such as hypoxia and 
starvation to gain survival/growth advantage. Altered glycolysis is thought to be a major 
driver, well known over decades as the Warburg effect, but other mechanisms remain elusive 
(Pan and Mak, 2007).  
Using a cDNA microarray screening, we identified carnitine palmitoyltransferase 1C (CPT1C) 
as a novel p53 target. Members of the carnitine palmitoyltransferase family play central roles 
in fatty acid metabolism and are localized to the mitochondrial membrane (reviewed in 
Bonnefont et al, 2004; Price et al, 2002; Wolfgang et al, 2006; Wolfgang et al, 2008). We 
show that the p53 target CPT1C is induced by hypoxia or glucose deprivation, and regulated 
by the metabolic sensor AMPKα. Cancer cells overexpressing CPT1C show increased 
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 proliferation, fatty acid oxidation (FAO) and ATP production, and are resistant to glucose 
deprivation, hypoxia or rapamycin. Conversely, cancer cells lacking CPT1C produce less ATP 
and are sensitive to hypoxia or glucose deprivation. We find that murine tumors with low 
mTOR activation and increased rapamycin resistance also show upregulation of the normally 
brain-restricted CPT1C isoform of carnitine palmitoyltransferase-1.  
Our results indicate that tumour cells protect themselves against metabolic stress via CPT1C 
induction, perhaps by making fatty acids to an alternative fuel source. Remarkably, CPT1C 
depletion synergizes with metformin, an AMPK activator, and suppresses tumour growth in 
xenograft models. CPT1C may therefore represent an exciting new therapeutic target for the 
treatment of hypoxic tumours.  
 
IV.2. Significance 
In the last 20 years, cancer therapy has improved such that we see an improved prognosis for 
most types of cancer.  This has been due to improved early-detection strategies as well as novel 
treatments and combination of treatment modalities.  For treatment of solid tumours, however, 
we still lack a means to sensitize the cancer cell to one of the most important stresses upon its 
growth, that is survival in low oxygen microenvironment (Semenza, 2011). Hypoxic 
environments have the further detriment to effective treatment by virtue of the requirement of 
cellular oxygen for ionizing radiation-induced DNA damage, and the direct correlation 
between tissue oxygen concentration and accessibility of the cell to chemotherapeutics. Hence, 
cells in the hypoxic microenvironment are more difficult to destroy by conventional treatments 
(Harris, 2002).  
Our study suggests that CPT1C may be therapeutically relevant. Firstly, CPT1C may be a 
useful biomarker for rapamycin resistance, allowing clinical selection of potential patient 
populations for effective treatment with mTOR inhibitors. Secondly, CPT1C may be an 
attractive target to affect tumors that are hypoxic and deprived of nutrients, and/or tumors that 
are resistant to mTOR inhibitors. Because CPT1C expression is normally brain-restricted, local 
administration of an agent targeting this protein would be unlikely to affect normal cells. A 
CPT1C inhibitor might therefore be a helpful addition to the cancer therapy armamentarium, 
used either as monotherapy or in combination with mTOR inhibitors. 
 It is our hope and expectation that, in time, effective treatments that function within the 
hypoxic microenvironment will be developed to allow better treatment options. At this point, 
CPT1C appears to be a promising target for such therapies as loss-of-function of this gene 
leads to enhanced hypoxia-sensitivity, thus distinguishing the target cancer cells from their 
properly oxygenated normal counterparts. 
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 V. The CPT1C 5'UTR contains a repressing upstream open reading frame that is 
regulated by cellular energy availability and AMPK. (Lohse, Reilly, and Zaugg, PLoS 
ONE, 2011) 
 
V.1. Summary 
 Translational control is an important regulator of gene expression (Morris et al, 2000). Based 
on our promising data on CPT1C we next investigated if posttranscriptional regulation of 
CPT1C might be one mean by which CPT1C’s expression is modified by metabolic stress. 
Indeed, we are able to show that CPT1C can be regulated through an upstream open reading 
frame (uORF) and that this regulation can be impacted by cellular energy availability and 
AMPK activity. This regulation describes a heretofore unseen mechanism for metabolic 
control of gene expression.   
 
 V.2. Significance 
The fact that regulation by the open reading frame of CPT1C is relieved in response to a 
specific set of stress stimuli, hints at an involvement of CPT1C in cellular energy-sensing 
pathways and provides further evidence for a role of the newly discovered p53 target CPT1C 
in metabolic stress pathways. Our studies of combining the individual derepressive stimuli 
would suggest either that AMPK and fatty acids may act in converging pathways for CPT1C 
uORF derepression, or act in a defined pathway whereby low carbohydrate concentration 
signals AMPK, as is known. AMPK may, in turn, then mobilize fatty acids that can then act to 
derepress the CPT1C uORF. Further biochemical studies will be necessary to elucidate the 
specific mechanism through which Palmitate and AMPK activation may control this 
translational derepression. 
 
 VI. Outlook 
Hypoxia, or a reduction in tissue-oxygen availability, is an important chronic stress on tumour-
cell growth.  Cancers that have increased resistance to hypoxia are more aggressive than 
tumours that are sensitive.  While therapeutic strategies are available that capitalize on chronic 
hypoxia sensitivity in tumours, primarily through intervention with angiogenesis, no cellular 
targets have been characterized that induce increase cellular sensitivity to hypoxia.  Carnitine 
Palmitoyltransferase 1C (CPT1C) may represent such a target since loss-of-function of this 
gene promotes severe cellular sensitivity to hypoxic stress and overexpression of CPT1C leads 
to a significant increase of cancer cell proliferation, migration and invasion (unpublished data), 
the first step of cancer cells to metastases. Elucidating the mechanism by which CPT1C 
influences the sensitivity to hypoxia and migration might give us a novel approach to decrease 
the threshold in hypoxic, otherwise treatment-resistant tumour cells. 
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